Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis

Liver International

Volumn 26, Issue 3, 2006, Pages 285-290

  Dilger, Karin ^a   Cascorbi, Ingolf ^b,c   Grünhage, Frank ^d   Hohenester, Simon ^e   Sauerbruch, Tilman ^d   Beuers, Ulrich ^e  

^a Dr Falk Pharma GmbH   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Budesonide; Cytochrome P450 3A; Drug resistance; MDR1; Primary biliary cirrhosis

Indexed keywords

ALANINE; BUDESONIDE; GLYCINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; THREONINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; ENZYME ACTIVITY; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; PRIMARY BILIARY CIRRHOSIS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BUDESONIDE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENES, MDR; GENOTYPE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644810639     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01222.x     Document Type: Article

References (39)

1. Schwab M, Eichelbaum M, Fromm M F. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285-307.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman M M, Pastan I, Willingham M C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
3. Zhang Y, Benet L Z. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-68.
4. Marzolini C, Paus E, Buclin T, Kim R B. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33.
5. Ueda K, Cardarelli C, Gottesman M M, Pastan I. Expression of full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-8.
6. Leuschner M, Maier K P, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology 1999; 117: 918-25.
7. Rautiainen H, Karkkainen P, Karvonen A L, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology 2005; 41: 747-52.
8. Möllmann H W, Barth J, Hochhaus G, Möllmann A C, Derendorf H, Tromm A. Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. In: Möllmann H W, May B, eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996; 42-60.
9. Greenberg G R, Feagan B G, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian inflammatory bowel disease study group. N Engl J Med 1994; 331: 836-41.
10. Dilger K, Schwab M, Fromm M F. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 2004; 10: 578-83.
11. Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995; 23: 137-42.
12. Guengerich F P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
13. Xie H G, Wood A J J, Kim R B, Stein C M, Wilkinson G R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72.
14. Farrell R J, Kelleher D. Mechanisms of steroid action and resistance in inflammation. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003; 178: 339-46.
15. Farrell R J, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279-88.
16. Zheng H, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Human Immunol 2002; 63: 765-70.
17. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202.
18. Dilger K, Denk A, Heeg M H J, Beuers U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 2005; 41: 595-602.
19. Wang Y, Tang Y, Moellmann H, Hochhaus G. Simultaneous quantification of budesonide and its two metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. Biomed Chromatogr 2003; 17: 158-64.
20. Heinzel G, Woloszczak R, Thomann P. TopFit Version 2.0: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. New York: Gustav Fischer, 1993.
21. Schall R, Hundt H K L, Luus H G. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies. Int J Clin Pharmacol Ther 1994; 32: 633-7.
22. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74.
23. Thervet E, Angelicheau D, King B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2002; 76: 1233-5.
24. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
25. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9.
26. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
27. Zheng H X, Webber S A, Zeevi A, et al. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transpl 2004; 8: 551-7.
28. Mayer U, Wagenaar E, Dorobek B, Beijnen J H, Borst P, Schinkel A H. Full blockade of intestinal P-glycoprotein and extensive inhibition of bloodbrain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430-6.
29. Cufer T, Vrhovec I, Pfeifer M, Skrk J, Borstener S, Sikic B I. Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemother Pharmacol 1998; 41: 517-21.
30. Farrell R J, Menconi M J, Keates A C, Kelly C P. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol Ther 2002; 16: 1021-31.
31. Evans W E, McLeod H L. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
32. Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-83.
33. Ieri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004; 43: 553-76.
34. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polmorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
35. Lin Y S, Dowling A L, Quigley S D, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-72.
36. Haufroid V, Mourad M, van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54.
37. Hesseling D A, van Schaik R H N, van der Heiden I P, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
38. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 27: 1182-7.
39. Katz D A, Grimm D R, Cassar S C, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004; 75: 516-28.